Published in J Crohns Colitis on January 14, 2011
Guidelines for video capsule endoscopy: emphasis on Crohn's disease. Clin Endosc (2015) 0.85
Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn's Disease: A Meta-Analysis. Gut Liver (2016) 0.84
Small bowel imaging in managing Crohn's disease patients. Gastroenterol Res Pract (2012) 0.78
Capsule Endoscopy for Crohn's Disease: Current Status of Diagnosis and Management. Gastroenterol Res Pract (2015) 0.78
A look into the small bowel in Crohn's disease. Clin Endosc (2012) 0.76
On the usefulness of small bowel capsule endoscopy in Crohn's disease. J Crohns Colitis (2011) 0.75
Small intestine contrast ultrasonography for the detection and assessment of Crohn disease: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study. Gut Liver (2016) 0.75
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol (2010) 1.66
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc (2006) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis (2007) 1.15
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol (2006) 1.11
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology (2002) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol (2006) 1.06
Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol (2011) 1.04
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev (2009) 1.03
Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis (2005) 1.03
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis (2005) 1.03
Aryl hydrocarbon receptor and colitis. Semin Immunopathol (2013) 1.02
Intestinal duplication in adulthood: A rare entity, difficult to diagnose. World J Gastrointest Surg (2011) 1.02
Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology (2004) 1.02
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis (2015) 1.01
Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci (2009) 1.00
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol (2007) 0.99
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood (2009) 0.99
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect Immun (2004) 0.98
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol (2009) 0.98
Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis (2013) 0.98
Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev (2010) 0.98
IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J Immunol (2011) 0.95
Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One (2013) 0.94
Medical and surgical treatment of haemorrhoids and anal fissure in Crohn's disease: a critical appraisal. BMC Gastroenterol (2013) 0.94
Laparoscopic versus open ileo-colonic resection in Crohn's disease: short- and long-term results from a prospective longitudinal study. J Gastrointest Surg (2007) 0.93
Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res (2011) 0.93
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World J Gastroenterol (2010) 0.92
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm Bowel Dis (2011) 0.92
Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis (2011) 0.92
Targeting interleukin-21 in inflammatory diseases. Expert Opin Ther Targets (2011) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis (2012) 0.91